Progyny (NASDAQ:PGNY) CFO Mark Livingston Sells 2,517 Shares of Stock

Posted by George Bondi on Jun 6th, 2026

Progyny, Inc. (NASDAQ:PGNY – Get Free Report) CFO Mark Livingston sold 2,517 shares of Progyny stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $25.50, for a total transaction of $64,183.50. Following the completion of the sale, the chief financial officer directly owned 74,688 shares of the company’s stock, valued at approximately $1,904,544. The trade was a 3.26% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Progyny Trading Up 1.5%

NASDAQ PGNY opened at $25.86 on Friday. The company has a fifty day simple moving average of $20.58 and a 200 day simple moving average of $22.30. Progyny, Inc. has a 12-month low of $16.10 and a 12-month high of $28.75. The company has a market cap of $2.03 billion, a P/E ratio of 33.58, a PEG ratio of 2.25 and a beta of 1.03.

Progyny (NASDAQ:PGNY – Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.26 by $0.24. Progyny had a net margin of 5.23% and a return on equity of 13.34%. The business had revenue of $328.50 million during the quarter, compared to the consensus estimate of $326.47 million. During the same quarter last year, the firm posted $0.17 EPS. Progyny’s revenue was down 26.4% compared to the same quarter last year. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. Sell-side analysts predict that Progyny, Inc. will post 1.07 EPS for the current year.

Progyny declared that its board has initiated a share buyback program on Tuesday, May 26th that permits the company to buyback $200.00 million in outstanding shares. This buyback authorization permits the company to repurchase up to 10.3% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s board of directors believes its shares are undervalued.

Hedge Funds Weigh In On Progyny

A number of hedge funds and other institutional investors have recently made changes to their positions in PGNY. Principal Financial Group Inc. raised its stake in Progyny by 57.1% in the 3rd quarter. Principal Financial Group Inc. now owns 704,267 shares of the company’s stock valued at $15,156,000 after acquiring an additional 256,078 shares during the period. Intech Investment Management LLC raised its stake in Progyny by 336.0% in the 3rd quarter. Intech Investment Management LLC now owns 169,834 shares of the company’s stock valued at $3,655,000 after acquiring an additional 130,885 shares during the period. Vanguard Group Inc. raised its stake in Progyny by 2.4% in the 3rd quarter. Vanguard Group Inc. now owns 10,106,147 shares of the company’s stock valued at $217,484,000 after acquiring an additional 235,513 shares during the period. Algert Global LLC raised its stake in Progyny by 35.1% in the 3rd quarter. Algert Global LLC now owns 595,805 shares of the company’s stock valued at $12,822,000 after acquiring an additional 154,930 shares during the period. Finally, Barclays PLC raised its stake in Progyny by 79.2% in the 3rd quarter. Barclays PLC now owns 1,575,470 shares of the company’s stock valued at $33,904,000 after acquiring an additional 696,447 shares during the period. 94.93% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on PGNY shares. Jefferies Financial Group reaffirmed a “buy” rating and set a $30.00 price objective on shares of Progyny in a report on Friday, March 6th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Progyny in a report on Friday, March 27th. Canaccord Genuity Group raised shares of Progyny from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $19.00 to $30.00 in a report on Tuesday, May 19th. Citigroup reaffirmed an “outperform” rating on shares of Progyny in a report on Monday, May 11th. Finally, Wall Street Zen raised shares of Progyny from a “hold” rating to a “buy” rating in a report on Saturday, April 18th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $29.67.

Check Out Our Latest Research Report on PGNY

About Progyny

(Get Free Report)

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.